Haemonetics Corporation $HAE Stock Position Lowered by Confluence Investment Management LLC

Confluence Investment Management LLC decreased its position in Haemonetics Corporation (NYSE:HAE) by 23.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 28,687 shares of the medical instruments supplier’s stock after selling 8,645 shares during the period. Confluence Investment Management LLC’s holdings in Haemonetics were worth $2,299,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC raised its stake in Haemonetics by 2,640.0% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 396 shares during the period. Versant Capital Management Inc lifted its holdings in shares of Haemonetics by 216.4% in the third quarter. Versant Capital Management Inc now owns 829 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 567 shares in the last quarter. Caitong International Asset Management Co. Ltd boosted its position in shares of Haemonetics by 20,925.0% in the third quarter. Caitong International Asset Management Co. Ltd now owns 841 shares of the medical instruments supplier’s stock worth $41,000 after buying an additional 837 shares during the period. Byrne Asset Management LLC purchased a new position in shares of Haemonetics during the third quarter valued at $42,000. Finally, Elevation Point Wealth Partners LLC purchased a new position in shares of Haemonetics during the second quarter valued at $64,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

HAE has been the subject of several research analyst reports. BTIG Research reissued a “buy” rating and issued a $88.00 price objective on shares of Haemonetics in a research note on Friday, February 6th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haemonetics in a research note on Monday, December 29th. CJS Securities upgraded Haemonetics to a “strong-buy” rating in a report on Thursday, December 11th. Needham & Company LLC lowered shares of Haemonetics from a “buy” rating to a “hold” rating in a research report on Monday, December 15th. Finally, JPMorgan Chase & Co. raised their price target on shares of Haemonetics from $62.00 to $74.00 and gave the stock a “neutral” rating in a report on Friday, December 12th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $83.89.

Haemonetics Stock Performance

Shares of HAE opened at $58.58 on Friday. The firm has a market cap of $2.72 billion, a price-to-earnings ratio of 16.14, a price-to-earnings-growth ratio of 1.23 and a beta of 0.28. The company’s fifty day moving average is $64.33 and its 200-day moving average is $64.82. The company has a quick ratio of 1.15, a current ratio of 1.75 and a debt-to-equity ratio of 1.01. Haemonetics Corporation has a 12 month low of $47.31 and a 12 month high of $87.32.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, February 5th. The medical instruments supplier reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.27 by $0.04. The business had revenue of $338.97 million during the quarter, compared to analyst estimates of $331.90 million. Haemonetics had a net margin of 13.31% and a return on equity of 27.32%. Haemonetics’s quarterly revenue was down 2.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.19 EPS. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. Equities analysts expect that Haemonetics Corporation will post 4.55 EPS for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.